This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

ZAVICEFTA® is indicated for the treatment of complicated urinary tract infections, including pyelonephritis1*

ZAVICEFTA is as effective as a carbapenem in patients with cUTI caused by Gram-negative pathogens2

RECAPTURE Phase III trial: 1033 hospitalised adults with cUTI

Patients with favourable clinical response at TOC (%)§

Baseline pathogens: Predominantly E. coli and K. pneumoniae including some ceftazidime-resistant strains.

Explore more

REPRISE Phase III trial:

333 hospitalised adults with a cUTI or cIA​​​​​​​I

View trial results

REPROVE Phase III trial:

879 hospitalised adults with HAP and VAP

View trial results

RECLAIM Phase III trial:

1066 hospitalised adults with cIAI​​​​​​​

View trial results

§Non-inferiority was concluded if the lower limit of the 95% CI was greater than –12.5%.
†The mMITT population comprised all randomised patients with minimum disease criteria and eligible baseline pathogen(s).
*Consideration should be given to official guidance on the appropriate use of antibacterial agents

Abbreviations:

AE, adverse event; CE, clinically evaluable; CI, confidence interval; cMITT, clinically modified intention-to-treat; HAP, hospital-acquired pneumonia; K. pneumoniae, Klebsiella pneumoniae; P. aeruginosa, Pseudomonas aeruginosa; TOC, test of cure; VAP, ventilator-associated pneumonia; cIAI, complicated intra-abdominal infection; E.coli, Escherichia coli; MITT, modified intention-to-treat; cUTI, complicated urinary tract infection. ​​​​​​​

Prescribing information

Zavicefta (ceftazidime and avibactam) 2g/0.5 g Powder for Concentrate for Solution for Infusion

Meronem® (meropenem triydrate) IV 1g

Meronem® (meropenem triydrate) IV 500mg​​​​​​​

Gentamicin (gentamicin sulfate) 40 mg/ml Injection
Legal Category: Prescription Only Medicine (POM)
NHS Price: 5 vial £20.00 
Click here for the Summary of Product Characteristics

References:
  1. ZAVICEFTA. Summary of Product Characteristics;
  2. Wagenlehner FM, et al. Clin Infect Dis 2016;63:754–62
PP-ZVA-GBR-0838. June 2021

Learn more about the tolerability data of ZAVICEFTA from four Phase III clinical trials.

View safety profile

Paschalis Vergidis

Listen to Paschalis Vergidis, Infectious Diseases Consultant at Manchester University NHS Foundation Trust, sharing his view on the challenges of MDR Gram-negative infections. Learn about his clinical practice experience in a renal transplant patient and the role of ceftazidime-avibactam in patients with  cUTI.

Card CTA

** This is an optional area where footnotes can live.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No